Health Care [ 4/12 ] | Biotechnology [ 13/75 ]
NASDAQ | Common Stock
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
The company operates in two segments, Pharmaceutical and Diagnostics.
The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system.
This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency.
The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test.
OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 19, 26 | -0.04 Decreased by -458.00% | -0.07 Increased by +46.65% |
| Oct 29, 25 | 0.03 Increased by +200.00% | -0.06 Increased by +150.00% |
| Jul 31, 25 | -0.19 Decreased by -1.80 K% | -0.11 Decreased by -67.70% |
| May 5, 25 | -0.09 Increased by +20.92% | -0.11 Increased by +13.73% |
| Feb 25, 25 | 0.01 Increased by +111.11% | -0.10 Increased by +110.00% |
| Nov 7, 24 | -0.03 Increased by +72.73% | -0.09 Increased by +66.67% |
| Aug 7, 24 | -0.01 Increased by +66.67% | -0.09 Increased by +88.89% |
| May 7, 24 | -0.12 Decreased by -500.00% | -0.09 Decreased by -33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 148.50 M Decreased by -19.13% | -31.30 M Decreased by -323.14% | Decreased by -21.08% Decreased by -375.94% |
| Sep 30, 25 | 151.67 M Decreased by -12.65% | 21.63 M Decreased by -13.09% | Increased by +14.26% Decreased by -0.51% |
| Jun 30, 25 | 156.81 M Decreased by -13.93% | -148.44 M Decreased by -1.34 K% | Decreased by -94.66% Decreased by -1.57 K% |
| Mar 31, 25 | 149.95 M Decreased by -13.66% | -67.61 M Increased by +17.38% | Decreased by -45.09% Increased by +4.30% |
| Dec 31, 24 | 183.64 M Increased by +0.96% | 14.03 M Increased by +121.10% | Increased by +7.64% Increased by +120.90% |
| Sep 30, 24 | 173.63 M Decreased by -2.78% | 24.89 M Increased by +129.47% | Increased by +14.33% Increased by +130.31% |
| Jun 30, 24 | 182.19 M Decreased by -31.36% | -10.30 M Increased by +47.53% | Decreased by -5.66% Increased by +23.56% |
| Mar 31, 24 | 173.69 M Decreased by -26.89% | -81.84 M Decreased by -348.00% | Decreased by -47.12% Decreased by -512.80% |